Literature DB >> 10858364

Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation.

A W Peng1, S Milleri, D S Stein.   

Abstract

In a single-center, randomized study, zanamivir (Relenza) concentrations in induced sputum samples and nasal washings of healthy adults following oral inhalation were measured. Concentrations in sputum exceeded the median viral neuraminidase 50% inhibitory concentration at 6, 12, and 24 h, and those in nasal washings did so at 6 and 12 h. There were no zanamivir-related adverse events or laboratory abnormalities.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10858364      PMCID： PMC89995          DOI： 10.1128/AAC.44.7.1974-1976.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-12-12       Impact factor: 79.321

2.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

Authors:  F G Hayden; A D Osterhaus; J J Treanor; D M Fleming; F Y Aoki; K G Nicholson; A M Bohnen; H M Hirst; O Keene; K Wightman
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

3.  Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution.

Authors:  S I Rennard; G Basset; D Lecossier; K M O'Donnell; P Pinkston; P G Martin; R G Crystal
Journal:  J Appl Physiol (1985)       Date:  1986-02

4.  Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers.

Authors:  L M Cass; J Brown; M Pickford; S Fayinka; S P Newman; C J Johansson; A Bye
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

5.  Importance of selected inhaler characteristics and acceptance of a new breath-actuated powder inhalation device.

Authors:  K Nielsen; L Okamoto; T Shah
Journal:  J Asthma       Date:  1997       Impact factor: 2.515

6.  Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.

Authors:  J M Barnett; A Cadman; D Gor; M Dempsey; M Walters; A Candlin; M Tisdale; P J Morley; I J Owens; R J Fenton; A P Lewis; E C Claas; G F Rimmelzwaan; R De Groot; A D Osterhaus
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 7.  Influenza, influenza vaccine, and amantadine/rimantadine.

Authors:  R K Zimmerman; F L Ruben; E R Ahwesh
Journal:  J Fam Pract       Date:  1997-08       Impact factor: 0.493

Review 8.  'Flu' and structure-based drug design.

Authors:  R C Wade
Journal:  Structure       Date:  1997-09-15       Impact factor: 5.006

9.  Liquid chromatographic-tandem mass spectrometric method for the determination of the neuraminidase inhibitor zanamivir (GG167) in human serum.

Authors:  G D Allen; S T Brookes; A Barrow; J A Dunn; C M Grosse
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-09-24

10.  Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables.

Authors:  G L Drusano; J A Bilello; D S Stein; M Nessly; A Meibohm; E A Emini; P Deutsch; J Condra; J Chodakewitz; D J Holder
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226
View more
  20 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

Authors:  Aeron C Hurt; Jessica K Holien; Ian G Barr
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

4.  Decreased neuraminidase activity is important for the adaptation of H5N1 influenza virus to human airway epithelium.

Authors:  Natalia A Ilyushina; Nicolai V Bovin; Robert G Webster
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 5.  Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

Authors:  Jennifer L McKimm-Breschkin
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

Review 6.  Zanamivir: from drug design to the clinic.

Authors:  M Elliott
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-12-29       Impact factor: 6.237

7.  Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects.

Authors:  Mark J Shelton; Mark Lovern; Judith Ng-Cashin; Lori Jones; Elizabeth Gould; Jennifer Gauvin; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

8.  CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.

Authors:  Kumiko Koyama; Makoto Takahashi; Masataka Oitate; Naoko Nakai; Hideo Takakusa; Shin-ichi Miura; Osamu Okazaki
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

9.  Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.

Authors:  Shuku Kubo; Takanori Tomozawa; Masayo Kakuta; Akane Tokumitsu; Makoto Yamashita
Journal:  Antimicrob Agents Chemother       Date:  2010-01-04       Impact factor: 5.191

10.  I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y.

Authors:  Jérome LeGoff; Dominique Rousset; Georges Abou-Jaoudé; Anne Scemla; Patricia Ribaud; Séverine Mercier-Delarue; Valérie Caro; Vincent Enouf; François Simon; Jean-Michel Molina; Sylvie van der Werf
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.